← Back to searchRecruitingRecruiting
The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
NCT06692972 · China-Japan Friendship Hospital
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Exploration of and Model Establishment of the Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
About this study
This study intends to retrospectively screen and include participants according to inclusion and exclusion criteria, and collect the clinical data of participants by previous medical records. Imaging tools will be used to quantify changes in the spatial location, diameter and volume of target lesions to evaluate tumor regression rate and radiotherapy efficacy, and to explore tumor regression pattern and establish model. In addition, the relationship between tumor regression rate, incidence of adverse radiation events, prognosis and related factors will be analysed.
Eligibility criteria
Inclusion Criteria:
1. Age ≥18 years old;
2. Stage II-III lung cancer with a clear pathological diagnosis report or medical record, not undergoing surgery before radiotherapy;
3. The primary lung lesion received definitive radiotherapy (defined as conventional fractionation radiotherapy with dose ≥50Gy, stereotactic radiotherapy with biologically effective dose ≥100Gy);
4. The target lesion of the lung receiving radiotherapy can be measured;
5. Imaging data can be obtained before and after radiotherapy;
6. Complete radiotherapy as planned, or the actual received dose has reached the defined definitive dose.
Exclusion Criteria:
1. Before radiotherapy, the primary lesion of the lung had received local treatment such as surgery or ablative treatment;
2. The radiotherapy plan was not completed, and the actual dose received did not reach the definitive dose (defined as conventional fractionation radiotherapy with dose \<50Gy, stereotactic radiotherapy with biologically effective dose \<100Gy);
3. Required imaging data cannot be obtained;
4. Other conditions considered by the investigator to be inappropriate for enrollment.
Study design
Enrollment target: 500 participants
Age groups: adult, older_adult
Timeline
Starts: 2024-12-25
Estimated completion: 2025-12-31
Last updated: 2025-02-27
Primary outcomes
- • Tumor regression rate (Within 1 year after completion of radiotherapy.)
Sponsor
China-Japan Friendship Hospital · other
Contacts & investigators
ContactGuangying Zhu, M.D. · contact · zryyfa@163.com · +86 010-84205380
InvestigatorGuangying Zhu, M.D. · principal_investigator, China-Japan Friendship Hospital
All locations (2)
China-Japan Friendship HospitalRecruiting
Beijing, Beijing Municipality, China
Renmin Hospital of Wuhan UniversityRecruiting
Wuhan, Hubei, China